Akari Therapeutics Company

Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. Akari’s lead drug, Coversin is a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex or MAC). C5 inhibition is growing in importance in a range of rare autoimmune diseases related to dysregulation of the complement component of the immune system, including paroxysmal nocturnal hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), and Guillain Barré syndrome (GBS).
Stock Symbol NASDAQ:AKTX
Technology: Scientifically-Validated Lifestyle Recommendation
Industry: Preventive Medicine
Headquarters: London, England, United Kingdom
Founded Date: 2005
Employees Number: 11-50
Funding Status: IPO

Visit Website
info@celsustx.com
Register and Claim Ownership